Literature DB >> 22077236

Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes.

Ian H de Boer, Wanjie Sun, Patricia A Cleary, John M Lachin, Mark E Molitch, Michael W Steffes, Bernard Zinman.   

Abstract

BACKGROUND: An impaired glomerular filtration rate (GFR) leads to end-stage renal disease and increases the risks of cardiovascular disease and death. Persons with type 1 diabetes are at high risk for kidney disease, but there are no interventions that have been proved to prevent impairment of the GFR in this population.
METHODS: In the Diabetes Control and Complications Trial (DCCT), 1441 persons with type 1 diabetes were randomly assigned to 6.5 years of intensive diabetes therapy aimed at achieving near-normal glucose concentrations or to conventional diabetes therapy aimed at preventing hyperglycemic symptoms. Subsequently, 1375 participants were followed in the observational Epidemiology of Diabetes Interventions and Complications (EDIC) study. Serum creatinine levels were measured annually throughout the course of the two studies. The GFR was estimated with the use of the Chronic Kidney Disease Epidemiology Collaboration formula. We analyzed data from the two studies to determine the long-term effects of intensive diabetes therapy on the risk of impairment of the GFR, which was defined as an incident estimated GFR of less than 60 ml per minute per 1.73 m(2) of body-surface area at two consecutive study visits.
RESULTS: Over a median follow-up period of 22 years in the combined studies, impairment of the GFR developed in 24 participants assigned to intensive therapy and in 46 assigned to conventional therapy (risk reduction with intensive therapy, 50%; 95% confidence interval, 18 to 69; P=0.006). Among these participants, end-stage renal disease developed in 8 participants in the intensive-therapy group and in 16 in the conventional-therapy group. As compared with conventional therapy, intensive therapy was associated with a reduction in the mean estimated GFR of 1.7 ml per minute per 1.73 m(2) during the DCCT study but during the EDIC study was associated with a slower rate of reduction in the GFR and an increase in the mean estimated GFR of 2.5 ml per minute per 1.73 m(2) (P<0.001 for both comparisons). The beneficial effect of intensive therapy on the risk of an impaired GFR was fully attenuated after adjustment for glycated hemoglobin levels or albumin excretion rates.
CONCLUSIONS: The long-term risk of an impaired GFR was significantly lower among persons treated early in the course of type 1 diabetes with intensive diabetes therapy than among those treated with conventional diabetes therapy. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and others; DCCT/EDIC ClinicalTrials.gov numbers, NCT00360815 and NCT00360893.).

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22077236      PMCID: PMC3270008          DOI: 10.1056/NEJMoa1111732

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  24 in total

1.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

Authors:  E J Lewis; L G Hunsicker; W R Clarke; T Berl; M A Pohl; J B Lewis; E Ritz; R C Atkins; R Rohde; I Raz
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

2.  Standards of medical care in diabetes--2011.

Authors: 
Journal:  Diabetes Care       Date:  2011-01       Impact factor: 19.112

3.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

Authors:  B M Brenner; M E Cooper; D de Zeeuw; W F Keane; W E Mitch; H H Parving; G Remuzzi; S M Snapinn; Z Zhang; S Shahinfar
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

Review 4.  Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials.

Authors:  Faramarz Ismail-Beigi; Etie Moghissi; Margaret Tiktin; Irl B Hirsch; Silvio E Inzucchi; Saul Genuth
Journal:  Ann Intern Med       Date:  2011-04-19       Impact factor: 25.391

5.  Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes.

Authors:  Toshiharu Ninomiya; Vlado Perkovic; Bastiaan E de Galan; Sophia Zoungas; Avinesh Pillai; Meg Jardine; Anushka Patel; Alan Cass; Bruce Neal; Neil Poulter; Carl-Erik Mogensen; Mark Cooper; Michel Marre; Bryan Williams; Pavel Hamet; Giuseppe Mancia; Mark Woodward; Stephen Macmahon; John Chalmers
Journal:  J Am Soc Nephrol       Date:  2009-05-14       Impact factor: 10.121

6.  Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study.

Authors:  Mark E Molitch; Michael Steffes; Wanjie Sun; Brandy Rutledge; Patricia Cleary; Ian H de Boer; Bernard Zinman; John Lachin
Journal:  Diabetes Care       Date:  2010-04-22       Impact factor: 19.112

7.  Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study.

Authors: 
Journal:  JAMA       Date:  2003-10-22       Impact factor: 56.272

8.  Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005).

Authors:  David M Nathan; Bernard Zinman; Patricia A Cleary; Jye-Yu C Backlund; Saul Genuth; Rachel Miller; Trevor J Orchard
Journal:  Arch Intern Med       Date:  2009-07-27

9.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.

Authors:  E J Lewis; L G Hunsicker; R P Bain; R D Rohde
Journal:  N Engl J Med       Date:  1993-11-11       Impact factor: 91.245

10.  Cystatin C, albuminuria, and mortality among older adults with diabetes.

Authors:  Ian H de Boer; Ronit Katz; Jie J Cao; Linda F Fried; Bryan Kestenbaum; Ken Mukamal; Dena E Rifkin; Mark J Sarnak; Michael G Shlipak; David S Siscovick
Journal:  Diabetes Care       Date:  2009-07-08       Impact factor: 19.112

View more
  192 in total

1.  Diabetes: Intensive glucose control in type 1 diabetes mellitus reduces risk of GFR loss.

Authors:  Susan J Allison
Journal:  Nat Rev Nephrol       Date:  2011-12-06       Impact factor: 28.314

2.  Diabetes: Intensive glucose control in type 1 diabetes mellitus reduces risk of GFR loss.

Authors:  Susan J Allison
Journal:  Nat Rev Endocrinol       Date:  2011-12-06       Impact factor: 43.330

3.  Diabetes: hyperfiltration-a risk factor for nephropathy in T1DM?

Authors:  Christos Chatzikyrkou; Hermann Haller
Journal:  Nat Rev Endocrinol       Date:  2012-04-24       Impact factor: 43.330

4.  Disease progress and response to treatment as predictors of survival, disability, cognitive impairment and depression in Parkinson's disease.

Authors:  Thuy C Vu; John G Nutt; Nicholas H G Holford
Journal:  Br J Clin Pharmacol       Date:  2012-08       Impact factor: 4.335

5.  Past Decline Versus Current eGFR and Subsequent Mortality Risk.

Authors:  David M J Naimark; Morgan E Grams; Kunihiro Matsushita; Corri Black; Iefke Drion; Caroline S Fox; Lesley A Inker; Areef Ishani; Sun Ha Jee; Akihiko Kitamura; Janice P Lea; Joseph Nally; Carmen Alicia Peralta; Dietrich Rothenbacher; Seungho Ryu; Marcello Tonelli; Hiroshi Yatsuya; Josef Coresh; Ron T Gansevoort; David G Warnock; Mark Woodward; Paul E de Jong
Journal:  J Am Soc Nephrol       Date:  2015-12-11       Impact factor: 10.121

Review 6.  MicroRNAs in diabetic nephropathy: functions, biomarkers, and therapeutic targets.

Authors:  Mitsuo Kato; Rama Natarajan
Journal:  Ann N Y Acad Sci       Date:  2015-04-15       Impact factor: 5.691

Review 7.  Diabetic kidney disease and the cardiorenal syndrome: old disease, new perspectives.

Authors:  Ankur Jindal; Mariana Garcia-Touza; Nidhi Jindal; Adam Whaley-Connell; James R Sowers
Journal:  Endocrinol Metab Clin North Am       Date:  2013-08-01       Impact factor: 4.741

Review 8.  Management of hyperglycemia in hospitalized patients with renal insufficiency or steroid-induced diabetes.

Authors:  David Baldwin; Jill Apel
Journal:  Curr Diab Rep       Date:  2013-02       Impact factor: 4.810

Review 9.  Hyperglycemia and vascular metabolic memory: truth or fiction?

Authors:  Cristina Bianchi; Roberto Miccoli; Stefano Del Prato
Journal:  Curr Diab Rep       Date:  2013-06       Impact factor: 4.810

Review 10.  Clinical therapeutic strategies for early stage of diabetic kidney disease.

Authors:  Munehiro Kitada; Keizo Kanasaki; Daisuke Koya
Journal:  World J Diabetes       Date:  2014-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.